Prostate cancer
RTOG 3506
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with PostProstatectomy PSA Recurrences with Aggressive
Topic
S1802
Disease
Prostate cancer
Description
Primary Objective The primary goal of this study is to determine whether, in men with postprostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.
Physicians
Frank A. Vicini
MD, FACR, FASTRO, FABS
Radiation Oncologist
Farmington Hills (Radiation oncology) +2
Eduardo B. Fernandez
MD, PhD, DABR, FACRO, FASTRO
Radiation Oncologist
Aventura (Radiation oncology) +3
